Wuxi Biologics (2269 HK): Expanded Offering and Capacity Drive 1H25 Result; Accelerated Growth Ahead
Per preliminary result, Wuxi Biologics expects 2025 revenue to rise 17% YoY to RMB22B and adjusted net profit to increase 22% YoY to RMB7B, driven...
587 Views
APAC Healthcare Weekly (August 23) – Henlius Bio, Wuxi XDC, Chugai Pharma, Daiichi Sankyo, Celltrion
Henlius strikes biosimilar commercialization deal with Sandoz. Chugai signs exclusive license deal with GSK for anti-dengue virus antibody....
100 Views
StubWorld: WuXi Biologics (2269 HK)'s Double Discounts; Melco (200 HK) Further Out Of Whack
WuXi XDC Cayman (2268 HK)'s Offer for BioDlink International (1875 HK) will add an additional discount layer to WuXi Biologics (2269 HK). Plus...
551 Views
China Healthcare Weekly (Jan.18)-Biotechs to Enter Hong Kong Stock Connect, Wuxi Biologics Placement
We shared our views about the biotechs that would be included in Hong Kong Stock Connect. WuXi Bio's Placement is interpreted negative as its...
382 Views
Wuxi Biologics Placement: Recent Deals Haven’t Done as Well
WuXi Biologics Holdings is looking to raise US$460m from a partial selldown of its stake in Wuxi Biologics. In this note, we will talk about the...
417 Views